ArticleWorld journal of urology2026

Determining the smallest worthwhile difference of beta-3 agonist treatment for overactive bladder: a benefit-harm trade-off study.

Kenji Omae et al.PubMed ↗Publisher ↗

No numbers read from the abstract.